Intravitreal nanoparticles for retinal delivery
- PMID: 31102730
- DOI: 10.1016/j.drudis.2019.05.005
Intravitreal nanoparticles for retinal delivery
Abstract
Intravitreal injection is one of the major administration routes for the treatment of posterior ocular diseases. Intravitreal therapeutics usually suffer from unsatisfactory efficacy owing to fast clearance from the vitreous humour and insufficient distribution into the retina. Engineered nanoparticles have been applied for specific tissue targeting over the past decades. In this review, we summarize the most recent research utilizing intravitreal nanoparticles to deliver therapeutics to the retina. Herein, the achievement made in preclinical research and challenges remaining in the field are highlighted. Parameters including size, charge, stability and choice of modified ligand on intraocular distribution and transport are also systematically discussed based on a proposed pharmacokinetic model. We provide insights for rational design principles for intravitreal nanoparticles for targeted retinal delivery.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Preclinical challenges for developing long acting intravitreal medicines.Eur J Pharm Biopharm. 2020 Aug;153:130-149. doi: 10.1016/j.ejpb.2020.05.005. Epub 2020 May 21. Eur J Pharm Biopharm. 2020. PMID: 32445965
-
Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection.Eur J Pharm Biopharm. 2017 Oct;119:125-136. doi: 10.1016/j.ejpb.2017.06.009. Epub 2017 Jun 8. Eur J Pharm Biopharm. 2017. PMID: 28602870
-
Noninvasive Monitoring of Choroid-Retina Autofluorescence and Intravitreal Nanoparticle Disposition in Royal College of Surgeon Rats of Different Ages and Retinal Thinning.J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):458-466. doi: 10.1089/jop.2020.0028. Epub 2020 Jun 18. J Ocul Pharmacol Ther. 2020. PMID: 32552217 Free PMC article.
-
Vitreous Humor: Composition, Characteristics and Implication on Intravitreal Drug Delivery.Curr Eye Res. 2023 Feb;48(2):208-218. doi: 10.1080/02713683.2022.2119254. Epub 2022 Nov 28. Curr Eye Res. 2023. PMID: 36036478 Review.
-
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.Adv Drug Deliv Rev. 2006 Nov 15;58(11):1164-81. doi: 10.1016/j.addr.2006.07.025. Epub 2006 Sep 16. Adv Drug Deliv Rev. 2006. PMID: 17069929 Review.
Cited by
-
Advances in Polysaccharide- and Synthetic Polymer-Based Vitreous Substitutes.Pharmaceutics. 2023 Feb 8;15(2):566. doi: 10.3390/pharmaceutics15020566. Pharmaceutics. 2023. PMID: 36839888 Free PMC article. Review.
-
The diagnosis and treatment progress of infectious endophthalmitis.Eye (Lond). 2025 Feb;39(3):492-504. doi: 10.1038/s41433-024-03474-7. Epub 2024 Nov 30. Eye (Lond). 2025. PMID: 39616279 Review.
-
Chondroitin Sulphate-Chitosan Based Nanogels Loaded with Naringenin-β-Cyclodextrin Complex as Potential Tool for the Treatment of Diabetic Retinopathy: A Formulation Study.Int J Nanomedicine. 2025 Jan 22;20:907-932. doi: 10.2147/IJN.S488507. eCollection 2025. Int J Nanomedicine. 2025. PMID: 39867306 Free PMC article.
-
Low-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis.Curr Res Pharmacol Drug Discov. 2022 May 11;3:100107. doi: 10.1016/j.crphar.2022.100107. eCollection 2022. Curr Res Pharmacol Drug Discov. 2022. PMID: 35647524 Free PMC article.
-
Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment.Drug Deliv. 2023 Dec;30(1):2204206. doi: 10.1080/10717544.2023.2204206. Drug Deliv. 2023. PMID: 37194147 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous